Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2396 - Comparison of acute hematologic and renal toxicities in two chemotherapy schedules of cisplatin for epithelial cell carcinoma of head and neck

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Ahmad Ameri

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

A. Ameri1, S. Norouzi1, A. Sourati1, K. Novin2, S. Azghandi3

Author affiliations

  • 1 Jorjani Cancer Center, Imam Hossein Hospital, 00 - Teheran/IR
  • 2 Radiation oncology Department, Shohada haftetir hospital, 00 - Teheran/IR
  • 3 Radiation oncology Department, Shohada Tajrish Hospital, 00 - Teheran/IR
More

Resources

Abstract 2396

Background

Standard approach for treatment of locally advanced head and neck carcinoma is concurrent chemoradiation with cisplatin 100mg/m2 every three week. However, prescribing cisplatin at this dose is associated with increased toxicity that can interrupt and compromise treatment results. Many centers use alternative schedules of weekly cisplatin at doses of 30-40 mg/m2 per week.

Methods

In this study, 77 patients with head and neck cancer were randomized in a phase II clinical trial to compare toxicity for two cisplatin schedules, 100mg/m2 three weekly and 40mg/m2 weekly.

Results

The incidence of grade 3-4 hematologic events was not significantly different between the two groups, but the mean level of glomerular filtration rate in the three weekly group was significantly higher than the weekly group. There was no significant difference between the two groups in terms of mean overall treatment time and mean dose of cisplatin. Cisplatin cumulative dose ≥ 200mg/m2 was higher in the weekly group, but no significant difference was observed. The main reason for treatment interruption was neutropenia for the three-weekly group, but in the weekly group, it was renal dysfunction for chemotherapy delay, and thrombocytopenia for radiotherapy break.

Conclusions

Weekly prescribing cisplatin can lead to higher cumulative doses, which may improve treatment outcomes. The incidence of grade 3-4 hematologic events was not significantly different between the two groups; However, the weekly schedule was associated with a higher drop in GFR, requiring further investigation.

Clinical trial identification

IRCT20180223038829N.

Legal entity responsible for the study

Shahid Beheshti University of Medical Science.

Funding

Research and Development Center of Shahid Beheshti University of Medical Science.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.